The effects of Ginger in treatment COVID-19

Phase 3

• Conditions: COVID-19 disease.; COVID-19, virus not identified; U07.2

• Registration Number: IRCT20200506047323N1
• Lead Sponsor: Bandare-abbas University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 November 2021

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 84

Inclusion Criteria

Age =18 years
Positive polymerase chain reaction (PCR) test for COVID-19 or/and lung involvement in imaging
Primary clinical symptoms
Hospitalized
Signing informed consent and willingness of study participant to accept randomization to any assigned treatment arm

Exclusion Criteria

Underlying diseases, including chronic hepatitis, cirrhosis, cholestatic liver diseases, cholecystitis, and peptic ulcers
Use of anticoagulant drugs like warfarin, and hormonal drugs
History of allergy to ginger
Pregnancy and breastfeeding

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
SARS-CoV-2 clearance. Timepoint: Before intervention and day 7. Method of measurement: PCR test.;Fever. Timepoint: Before intervention and daily during the study. Method of measurement: Thermometer.;White blood cell count. Timepoint: Before intervention and day 7. Method of measurement: Labratory.

Secondary Outcome Measures

Name	Time	Method
Hospital admission. Timepoint: During the intervention. Method of measurement: Questionnaire.;Incidence of serious adverse events. Timepoint: Before intervention and daily during the study. Method of measurement: Questionnaire.